L LABORATORY CORP AMER HLDGS
| Market Cap | $22.69B |
| P/E Ratio | 26.17 |
| Forward P/E | 14.19 |
| Dividend Yield | 1.05% |
| Beta | 0.98 |
| 52W Range | $209.97 - $289.43 |
| # Hedge Funds | 4 |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
Hedge Fund Ownership
| Investor 4 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Wallace Weitz Weitz Investment Management | 1.48% | $25.02M | 99,750 | Reduce 28.62% |
| Charles Bobrinskoy Ariel Investments | 0.98% | $90.34M | 360,087 | Reduce 0.77% |
| Jensen Investment Management Jensen Investment Management | 0.09% | $5.72M | 22,820 | Reduce 9.23% |
| Lee Ainslie Maverick Capital | 0.05% | $4.41M | 17,564 | Add 73.06% |
Insider Trading
| Insider Name of the company insider who made the trade 14 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Peter J WilkinsonSVP, Chief Accounting Officer | Sale | 1,633 | $267.05 | $436.09K | 27 Mar 2026 | 30 Mar 2026 |
| Jonathan C MeltzerEVP, Operations | Sale | 839 | $267.05 | $224.05K | 27 Mar 2026 | 30 Mar 2026 |
| Schechter Adam HPresident & CEO | Sale | 8,705 | $279.96 | $2.44M | 03 Mar 2026 | 05 Mar 2026 |
| van der Vaart Sandra DEVP, Corporate Affairs | Sale | 547 | $284.91 | $155.85K | 27 Feb 2026 | 03 Mar 2026 |
| Caveney Brian JEVP, Pres of ED, CMO & CSO | Sale | 1,500 | $286.31 | $429.46K | 24 Feb 2026 | 26 Feb 2026 |
| Wilkinson Peter JSVP, Chief Accounting Officer | Sale | 666 | $277.94 | $185.11K | 19 Feb 2026 | 23 Feb 2026 |
| Meltzer Jonathan CEVP, Operations | Sale | 87 | $290.42 | $25.27K | 12 Feb 2026 | 13 Feb 2026 |
| Schechter Adam HPresident & CEO | Sale | 5,273 | $284.38 | $1.50M | 11 Feb 2026 | 13 Feb 2026 |
| Meltzer Jonathan CEVP, Operations | Sale | 91 | $276.79 | $25.19K | 10 Feb 2026 | 12 Feb 2026 |
| Meltzer Jonathan CEVP, Operations | Sale | 88 | $275.53 | $24.25K | 09 Feb 2026 | 10 Feb 2026 |
| Jonathan C MeltzerEVP, Operations | Sale | 88 | $275.53 | $24.25K | 09 Feb 2026 | 10 Feb 2026 |
| Schechter Adam HPresident & CEO | Sale | 5,745 | $262.75 | $1.51M | 11 Nov 2025 | 13 Nov 2025 |
| Parham Richelle P | Sale | 7,009 | $254.28 | $1.78M | 31 Oct 2025 | 04 Nov 2025 |
| Richelle P ParhamDirector | Sale | 7,009 | $254.28 | $1.78M | 31 Oct 2025 | 04 Nov 2025 |
Frequently Asked Questions
What is LH stock price today?
LABORATORY CORP AMER HLDGS (LH) is currently trading at $273.72. The stock has a 52-week range of $209.97 to $289.43 and a market capitalization of $22.69B.
Is LH a good stock to buy in 2026?
LABORATORY CORP AMER HLDGS has a P/E ratio of 26.2 (forward P/E: 14.2), a dividend yield of 1.05%, and 1-year performance of +18.5%. 4 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling LH stock?
There have been 14 insider transactions for LH in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has LH stock performed over the past year?
LABORATORY CORP AMER HLDGS (LH) has returned +18.5% over the past 12 months. The stock traded between $209.97 and $289.43 during this period, and is currently at $273.72.
Which hedge funds own LH (LABORATORY CORP AMER HLDGS)?
4 tracked hedge funds currently hold LH in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is LH's market cap and valuation?
LABORATORY CORP AMER HLDGS (LH) has a market capitalization of $22.69B. The trailing P/E ratio is 26.2 and forward P/E is 14.2. The stock is classified in the Healthcare sector.
What is LH's revenue and profitability?
LABORATORY CORP AMER HLDGS reported revenue of $13.95B with net income of $876.50M and a profit margin of 0.06%. The stock has a beta of 0.98.
What sector is LH in and who are its biggest institutional holders?
LABORATORY CORP AMER HLDGS (LH) operates in the Healthcare sector. It is held by 4 tracked hedge funds. See the ownership table above for the complete list.